Tackling myocardial oxidative stress with empagliflozin: are we big enough to fight heart failure with preserved ejection fraction?

This editorial refers to ‘Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation’, by D. Kolijnet al., pp. 495 –507.
Source: Cardiovascular Research - Category: Cardiology Source Type: research